Updated COVID Shot Linked to Added Protection - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Updated COVID Shot Linked to Added Protection

Updated 2025-2026 vaccination was linked to added protection in a CDC-funded analysis that became part of a broader debate over routine vaccine monitoring.

  • By

  • Andrea Surnit

  • June 25, 2026

  • 6 min

Share

Clinical Report: Updated COVID Shot Linked to Added Protection

Overview

The 2025-2026 COVID-19 vaccine demonstrated 50% effectiveness against emergency department visits and 55% against hospitalizations among immunocompetent adults.

Background

The ongoing evolution of SARS-CoV-2 necessitates continuous updates to vaccination strategies. Understanding the effectiveness of new vaccine formulations is crucial for public health, especially as COVID-19 continues to impact healthcare systems.

Data Highlights

OutcomeEffectiveness
ED/UC Encounters50%
Hospitalizations55%

Key Findings

  • The 2025-2026 COVID-19 vaccine showed 50% effectiveness against COVID-19-associated ED/UC encounters.
  • Effectiveness against COVID-19-associated hospitalization was estimated at 55%.
  • Among adults aged 65 years or older, effectiveness was 48% for ED/UC encounters and 53% for hospitalizations.
  • Findings primarily reflect short-term protection, with median time since vaccination being 47 days for ED/UC encounters.
  • The study included data from 253 ED/UC sites and 179 hospitals across 7 US states.
  • COVID-19 was associated with an estimated 390,000 to 550,000 hospitalizations in the US from October 2024 to September 2025.

Clinical Implications

Healthcare providers should consider the effectiveness of the 2025-2026 COVID-19 vaccine when advising patients.

Conclusion

The interim data indicates that the 2025-2026 COVID-19 vaccine provides significant protection against severe outcomes in adults.

Related Resources & Content

  1. CDC, Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design, 2025 -- Vaccine Effectiveness Study
  2. MDSpire News — Recent COVID-19 Shot Linked to Less Spread
  3. MDSpire News — Small Shingles Risk Seen Post mRNA COVID-19 Booster
  4. MDSpire News — COVID-19 Booster in Pregnancy Linked to Higher Infant Antibodies
  5. MDSpire News — Extra COVID Vaccine May Reduce Long Symptoms
  6. 2025–2026 COVID-19 Vaccination Guidance | Covid | CDC
  7. COVID-19 Vaccines (2025-2026 Formula) for Use in the United States Beginning in Fall 2025 | FDA
  8. Implementation Guidance | Covid | CDC
  9. Overview of COVID-19 Vaccines and Vaccination | Covid | CDC
  10. ACIP Recommends COVID-19 Immunization Based on Individual Decision-making | HHS.gov
  11. Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design - PubMed
  12. Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design - PMC
  13. Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025 | MMWR
  14. https://cdn.who.int/media/docs/default-source/crs-crr/2026-04-01-epiwin_grt-mcm.pdf?sfvrsn=7a98f6bb_1
  15. https://cdn.who.int/media/docs/default-source/_sage-2026/final-highlights_18-march-2026.pdf
  16. IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19, Influenza, and RSV Infections in Immunocompromised Patients | Clinical Infectious Diseases | Oxford Academic
  17. ACP Says Adults at Increased Risk Should Get an mRNA-Based COVID-19 Vaccine | ACP Online

Original Source(s)

Updated COVID Shot Linked to Added Protection

  • by Andrea Surnit

  • June 25, 2026

Related Content

Extended antiviral therapy may not improve long COVID

Nirmatrelvir–ritonavir for up to 25 days failed to improve cognitive, autonomic, or exercise symptoms compared with placebo in a phase 2 trial.

PrEP surfing common among MSM

Reliance on partners’ PrEP use was more common among younger men and those who had used PrEP in the previous 6 months.

The rationale for ophthalmic vigilance during the 2026 Hantavirus outbreak